生命科学资讯
生物技术与制药领域的最新动态
Exclusive: Claim Health raises $4.4M to help home care providers get paid
Fosun-funded Hygtia Therapeutics licenses Insilico’s NLRP3 inhibitor for Parkinson’s
Think Bioscience gets $55M to unearth new drug pockets
政府拨款法案包含药品福利管理改革与代金券重新授权内容。
Government funding bill features PBM reforms, voucher reauthorization
欧盟议会通过《关键药品法案》下更严格的药品储备规定
EU Parliament adopts stricter drug stockpiling rules under Critical Medicines Act
Valneva撤回美国基孔肯雅热疫苗
Valneva withdraws chikungunya vaccine from US
临床医生团体请求法院推翻CDC儿童疫苗改革方案。
Clinician groups ask court to overturn CDC's childhood vaccine overhaul
Aspect Bio接手诺和诺德弃置疗法；武田制药削减美国职位。
Aspect Bio takes Novo castoff therapies; Takeda trims US jobs
Teladoc心理健康部门BetterHelp悄然扩大AI应用范围
Teladoc’s mental health arm BetterHelp has quietly expanded the use of AI
2025年收官强劲，并购、私募投资及增发市场第四季度表现活跃。
2025 ended on high note with a buoyant Q4 for M&A, PIPEs and follow-ons
辉瑞退出葛兰素史克ViiV，盐野义制药持股翻倍。
Pfizer to depart GSK's ViiV as Shionogi doubles its stake
强生与Isomorphic签署AI分子研究协议。
J&J, Isomorphic sign research deal for AI-made molecules
葛兰素史克以22亿美元收购RAPT及其食物过敏候选药物。
GSK makes $2.2B deal for RAPT and its food allergy candidate
Exciva完成5900万美元B轮融资，用于资助阿尔茨海默病激动药物二期试验。
Exciva raises $59M Series B to fund Phase 2 test of Alzheimer’s agitation drug
摩根大通回顾；米拉多尔融资2.5亿美元；基因泰克调整药品福利管理策略；及其他动态
JPM recap; Mirador raises $250M; Genentech’s PBM shift; and more
随着摩根大通后投资者热情高涨，Agomab与SpyGlass递交IPO申请。
Agomab and SpyGlass file for IPOs as investor enthusiasm builds after JPM
艾伯维与Genmab宣布Epkinly在淋巴瘤研究中未能延长总生存期。
AbbVie, Genmab say Epkinly didn't prolong overall survival in lymphoma study
未获最惠国待遇的制药商正加紧争取达成协议
Drugmakers without MFN pacts are bracing to make one
最高法院将审理希克玛与阿玛林之间的“瘦身标签”诉讼案。
Supreme Court will hear Hikma’s ‘skinny label’ fight against Amarin